Damora Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $26.9M | $6.4M | $23.8M | $48.2M | $38.5M |
| Operating expenses | $210.9M | $22.3M | $39.9M | $61.2M | $52.2M |
| Operating income | -$210.9M | -$22.3M | -$39.9M | -$61.2M | -$52.2M |
| Pretax income | -$209.8M | -$21.4M | -$38.3M | -$61.6M | -$51.8M |
| Income tax expense | $50,000 | $41,000 | $0 | $0 | $0 |
| Net income | -$209.8M | -$21.4M | -$38.3M | -$61.6M | -$51.8M |
| Balance Sheet | |||||
| Cash and equivalents | $257.6M | $14.2M | $21.5M | $32.8M | $62.6M |
| Current assets | $260.4M | $16.8M | $36.8M | $63.9M | $110.1M |
| Total assets | $260.5M | $17.1M | $38.2M | $73.2M | $122.2M |
| Current liabilities | $20.1M | $1.2M | $5.8M | $11.1M | $4.5M |
| Total liabilities | $20.1M | $1.3M | $5.9M | $11.4M | $5.0M |
| Stockholders' equity | $240.4M | $15.8M | $32.3M | $61.8M | $117.2M |
| Cash Flow Statement | |||||
| Cash from operations | -$6.7M | -$18.6M | -$36.9M | -$42.9M | -$52.3M |
| Depreciation and amortization | $22,000 | $21,000 | $269,000 | $42,000 | $20,000 |
| Stock-based compensation | $998,000 | $3.2M | $5.4M | $5.6M | $4.5M |
| Capital expenditure | — | — | — | $196,000 | $223,000 |
| Free cash flow | — | — | — | -$43.1M | -$52.5M |
Shares outstanding 61.6M · Free float 78.4%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.